留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

间充质干细胞在器官移植中发挥免疫抑制作用及机制探讨的研究进展

张礼翼 仝彩玲 安珂 钟佳颖 于胜男 林清如 马云瀚 陈映宇 夏俊杰 齐忠权

张礼翼, 仝彩玲, 安珂, 等. 间充质干细胞在器官移植中发挥免疫抑制作用及机制探讨的研究进展[J]. 器官移植, 2019, 10(5): 612-616. doi: 10.3969/j.issn.1674-7445.2019.05.025
引用本文: 张礼翼, 仝彩玲, 安珂, 等. 间充质干细胞在器官移植中发挥免疫抑制作用及机制探讨的研究进展[J]. 器官移植, 2019, 10(5): 612-616. doi: 10.3969/j.issn.1674-7445.2019.05.025
Zhang Liyi, Tong Calling, An Ke, et al. Research progress on immunosuppressive effect and mechanism of mesenchymal stem cells in organ transplantation[J]. ORGAN TRANSPLANTATION, 2019, 10(5): 612-616. doi: 10.3969/j.issn.1674-7445.2019.05.025
Citation: Zhang Liyi, Tong Calling, An Ke, et al. Research progress on immunosuppressive effect and mechanism of mesenchymal stem cells in organ transplantation[J]. ORGAN TRANSPLANTATION, 2019, 10(5): 612-616. doi: 10.3969/j.issn.1674-7445.2019.05.025

间充质干细胞在器官移植中发挥免疫抑制作用及机制探讨的研究进展

doi: 10.3969/j.issn.1674-7445.2019.05.025
基金项目: 

国家重点研发项目 2018YFA0108304

国家自然科学基金 81771721

国家自然科学基金 81671583

详细信息
    作者简介:

    张礼翼,男,1993年生,硕士研究生,研究方向为器官移植与干细胞,Email:289443035@qq.com

    通讯作者:

    夏俊杰,男,1985年生,博士,高级实验师,研究方向为器官移植、免疫学及干细胞,Email:xia@xmu.edu.cn

    齐忠权,男,1960年生,博士后,教授,研究方向为器官移植、免疫学及干细胞,Email:zqqi@xmu.edu.cn

  • 中图分类号: R617, R392.4

Research progress on immunosuppressive effect and mechanism of mesenchymal stem cells in organ transplantation

  • 摘要: 器官移植是终末期器官衰竭患者最有效的治疗手段。将间充质干细胞(MSC)用于器官移植已成为细胞疗法的重要组成部分。然而,MSC发挥免疫抑制作用的机制还有待进一步地挖掘,且影响MSC发挥免疫抑制作用的因素很多,这些原因导致MSC难以达到预期疗效。在本综述中将通过介绍MSC的免疫抑制作用及机制、影响MSC发挥免疫抑制作用的因素以及MSC的临床应用等方面来阐述MSC在器官移植领域的研究进展。

     

  • [1] HOOGDUIJN MJ, LOMBARDO E. Concise review: mesenchymal stromal cells anno 2019: dawn of the therapeutic era?[J]. Stem Cells Transl Med, 2019, DOI:10.1002/sctm.19-0073[Epub ahead of print].
    [2] VAN MEGEN KM, VAN'T WOUT ET, LAGES MOTTA J, et al. Activated mesenchymal stromal cells process and present antigens regulating adaptive immunity[J]. Front Immunol, 2019, 10:694. DOI: 10.3389/fimmu.2019.00694.
    [3] LUK F, CARRERAS-PLANELLA L, KOREVAAR SS, et al. Inflammatory conditions dictate the effect of mesenchymal stem or stromal cells on B cell function[J]. Front Immunol, 2017, 8:1042. DOI: 10.3389/fimmu.2017.01042.
    [4] CHO DI, KIM MR, JEONG HY, et al. Mesenchymal stem cells reciprocally regulate the M1/M2 balance in mouse bone marrow-derived macrophages[J]. Exp Mol Med, 2014, 46:e70. DOI: 10.1038/emm.2013.135.
    [5] VASANDAN AB, JAHNAVI S, SHASHANK C, et al. Human mesenchymal stem cells program macrophage plasticity by altering their metabolic status via a PGE2-dependent mechanism[J]. Sci Rep, 2016, 6:38308. DOI: 10.1038/srep38308.
    [6] PRIGIONE I, BENVENUTO F, BOCCA P, et al. Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells[J]. Stem Cells, 2009, 27(3):693-702. DOI: 10.1634/stemcells.2008-0687.
    [7] DAVIES LC, HELDRING N, KADRI N, et al. Mesenchymal stromal cell secretion of programmed death-1 ligands regulates T cell mediated immunosuppression[J]. Stem Cells, 2017, 35(3):766-776. DOI: 10.1002/stem.2509.
    [8] GALLEU A, RIFFO-VASQUEZ Y, TRENTO C, et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation[J]. Sci Transl Med, 2017, 9(416). DOI: 10.1126/scitranslmed.aam7828.
    [9] GALIPEAU J, SENSÉBÉ L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities[J]. Cell Stem Cell, 2018, 22(6):824-833. DOI: 10.1016/j.stem.2018.05.004.
    [10] CASTRO-MANRREZA ME, MONTESINOS JJ. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications[J]. J Immunol Res, 2015:394917. DOI: 10.1155/2015/394917.
    [11] KOCAN B, MAZIARZ A, TABARKIEWICZ J, et al. Trophic activity and phenotype of adipose tissue-derived mesenchymal stem cells as a background of their regenerative potential[J]. Stem Cells Int, 2017:1653254. DOI: 10.1155/2017/1653254.
    [12] ALANAZI A, MUNIR H, ALASSIRI M, et al. Comparative adhesive and migratory properties of mesenchymal stem cells from different tissues[J]. Biorheology, 2019, 56(1):15-30. DOI: 10.3233/BIR-180185.
    [13] JARVINEN L, BADRI L, WETTLAUFER S, et al. Lung resident mesenchymal stem cells isolated from human lung allografts inhibit T cell proliferation via a soluble mediator[J]. J Immunol, 2008, 181(6):4389-4396. doi: 10.4049/jimmunol.181.6.4389
    [14] PLOCK JA, SCHNIDER JT, ZHANG W, et al. Adipose- and bone marrow-derived mesenchymal stem cells prolong graft survival in vascularized composite allotransplantation[J]. Transplantation, 2015, 99(9):1765-1773. DOI: 10.1097/TP.0000000000000731.
    [15] EGGENHOFER E, RENNER P, SOEDER Y, et al. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model[J]. Transpl Immunol, 2011, 25(2/3):141-147. DOI: 10.1016/j.trim.2011.06.002.
    [16] ESTRADA JC, ALBO C, BENGURÍA A, et al. Culture of human mesenchymal stem cells at low oxygen tension improves growth and genetic stability by activating glycolysis[J]. Cell Death Differ, 2012, 19(5):743-755. DOI: 10.1038/cdd.2011.172.
    [17] KADLE RL, ABDOU SA, VILLARREAL-PONCE AP, et al. Microenvironmental cues enhance mesenchymal stem cell-mediated immunomodulation and regulatory T-cell expansion[J]. PLoS One, 2018, 13(3):e0193178. DOI: 10.1371/journal.pone.0193178.
    [18] FOTIA C, MASSA A, BORIANI F, et al. Hypoxia enhances proliferation and stemness of human adipose-derived mesenchymal stem cells[J]. Cytotechnology, 2015, 67(6):1073-1084. DOI: 10.1007/s10616-014-9731-2.
    [19] ZHU C, YU J, PAN Q, et al. Hypoxia-inducible factor-2 alpha promotes the proliferation of human placenta-derived mesenchymal stem cells through the MAPK/ERK signaling pathway[J]. Sci Rep, 2016, 6:35489. DOI: 10.1038/srep35489.
    [20] LV B, LI F, FANG J, et al. Hypoxia inducible factor 1α promotes survival of mesenchymal stem cells under hypoxia[J]. Am J Transl Res, 2017, 9(3):1521-1529. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xdkf201623006
    [21] LIU C, TSAI AL, LI PC, et al. Endothelial differentiation of bone marrow mesenchyme stem cells applicable to hypoxia and increased migration through Akt and NFκB signals[J]. Stem Cell Res Ther, 2017, 8(1):29. DOI: 10.1186/s13287-017-0470-0.
    [22] LAN YW, CHOO KB, CHEN CM, et al. Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis[J]. Stem Cell Res Ther, 2015, 6:97. DOI: 10.1186/s13287-015-0081-6.
    [23] JIANG CM, LIU J, ZHAO JY, et al. Effects of hypoxia on the immunomodulatory properties of human gingiva-derived mesenchymal stem cells[J]. J Dent Res, 2015, 94(1):69-77. DOI: 10.1177/0022034514557671.
    [24] WOBMA HM, KANAI M, MA SP, et al. Dual IFN-γ/hypoxia priming enhances immunosuppression of mesenchymal stromal cells through regulatory proteins and metabolic mechanisms[J]. J Immunol Regen Med, 2018, 1:45-56. DOI: 10.1016/j.regen.2018.01.001.
    [25] SALA E, GENUA M, PETTI L, et al. Mesenchymal stem cells reduce colitis in mice via release of TSG6, independently of their localization to the intestine[J]. Gastroenterology, 2015, 149(1):163-176. DOI: 10.1053/j.gastro.2015.03.013.
    [26] HAJKOVA M, HERMANKOVA B, JAVORKOVA E, et al. Mesenchymal stem cells attenuate the adverse effects of immunosuppressive drugs on distinct T cell subopulations[J]. Stem Cell Rev, 2017, 13(1):104-115. DOI: 10.1007/s12015-016-9703-3.
    [27] INOUE S, POPP FC, KOEHL GE, et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model[J]. Transplantation, 2006, 81(11):1589-1595. doi: 10.1097/01.tp.0000209919.90630.7b
    [28] HAJKOVA M, JAVORKOVA E, ZAJICOVA A, et al. A local application of mesenchymal stem cells and cyclosporine A attenuates immune response by a switch in macrophage phenotype[J]. J Tissue Eng Regen Med, 2017, 11(5):1456-1465. DOI: 10.1002/term.2044.
    [29] GE W, JIANG J, BAROJA ML, et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance[J]. Am J Transplant, 2009, 9(8):1760-1772. DOI: 10.1111/j.1600-6143.2009.02721.x.
    [30] SONG Y, WANG Z, WANG Z, et al. Use of FK506 and bone marrow mesenchymal stem cells for rat hind limb allografts[J]. Neural Regen Res, 2012, 7(34):2681-2688. DOI: 10.3969/j.issn.1673-5374.2012.34.005.
    [31] AN JH, SONG WJ, LI Q, et al. Prostaglandin E2 secreted from feline adipose tissue-derived mesenchymal stem cells alleviate DSS-induced colitis by increasing regulatory T cells in mice[J]. BMC Vet Res, 2018, 14(1):354. DOI: 10.1186/s12917-018-1684-9.
    [32] WILLIS GR, FERNANDEZ-GONZALEZ A, ANASTAS J, et al.Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation[J]. Am J Respir Crit Care Med, 2018, 197(1):104-116. DOI: 10.1164/rccm.201705-0925OC.
    [33] RIAZIFAR M, MOHAMMADI MR, PONE EJ, et al. Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders[J]. ACS Nano, 2019, 13(6):6670-6688. DOI: 10.1021/acsnano.9b01004.
    [34] KORDELAS L, REBMANN V, LUDWIG AK, et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease[J]. Leukemia, 2014, 28(4):970-973. DOI: 10.1038/leu.2014.41.
    [35] HABERTHEUER A, KORUTLA L, ROSTAMI S, et al. Donor tissue-specific exosome profiling enables noninvasive monitoring of acute rejection in mouse allogeneic heart transplantation[J]. J Thorac Cardiovasc Surg, 2018, 155(6):2479-2489. DOI: 10.1016/j.jtcvs.2017.12.125.
    [36] LIU Z, ZHANG Y, XIAO H, et al. Cotransplantation of bone marrow-derived mesenchymal stem cells in haploidentical hematopoietic stem cell transplantation in patients with severe aplastic anemia: an interim summary for a multicenter phase Ⅱ trial results[J]. Bone Marrow Transplant, 2017, 52(7):1080. DOI: 10.1038/bmt.2017.85.
    [37] GOTO T, MURATA M, TERAKURA S, et al. Phase Ⅰ study of cord blood transplantation with intrabone marrow injection of mesenchymal stem cells: a clinical study protocol[J]. Medicine (Baltimore), 2018, 97(17):e0449. DOI: 10.1097/MD.0000000000010449.
    [38] CETIN M, AKYOL G, GONEN ZB, et al. Additional infusions of mesenchymal stem cells improve response rate in multidrug-resistant GVHD patients[J]. Bone Marrow Transplant, 2017, 52(5):783-785. DOI: 10.1038/bmt.2017.1.
    [39] JURADO M, DE LA MATA C, RUIZ-GARCÍA A, et al. Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: a phase Ⅰ/Ⅱ study[J]. Cytotherapy, 2017, 19(8):927-936. DOI: 10.1016/j.jcyt.2017.05.002.
    [40] DOTOLI GM, DE SANTIS GC, ORELLANA MD, et al. Mesenchymal stromal cell infusion to treat steroid-refractory acute GVHD Ⅲ/Ⅳ after hematopoietic stem cell transplantation[J]. Bone Marrow Transplant, 2017, 52(6):859-862. DOI: 10.1038/bmt.2017.35.
    [41] WANG Z, YU H, CAO F, et al. Donor-derived marrow mesenchymal stromal cell co-transplantation following a haploidentical hematopoietic stem cell transplantation trail to treat severe aplastic anemia in children[J]. Ann Hematol, 2019, 98(2):473-479. DOI: 10.1007/s00277-018-3523-2.
    [42] SALMENNIEMI U, ITÄLÄ-REMES M, NYSTEDT J, et al. Good responses but high TRM in adult patients after MSC therapy for GVHD[J]. Bone Marrow Transplant, 2017, 52(4):606-608. DOI: 10.1038/bmt.2016.317.
    [43] VANIKAR AV, TRIVEDI HL, KUMAR A, et al. Co-infusion of donor adipose tissue-derived mesenchymal and hematopoietic stem cells helps safe minimization of immunosuppression in renal transplantation - single center experience[J]. Ren Fail, 2014, 36(9):1376-1384. DOI: 10.3109/0886022X.2014.950931.
    [44] PAN GH, CHEN Z, XU L, et al. Low-dose tacrolimus combined with donor-derived mesenchymal stem cells after renal transplantation: a prospective, non-randomized study[J]. Oncotarget, 2016, 7(11):12089-12101. DOI: 10.18632/oncotarget.7725.
    [45] DETRY O, VANDERMEULEN M, DELBOUILLE MH, et al. Infusion of mesenchymal stromal cells after deceased liver transplantation: a phase Ⅰ-Ⅱ, open-label, clinical study[J]. J Hepatol, 2017, 67(1):47-55. DOI: 10.1016/j.jhep.2017.03.001.
    [46] PERICO N, CASIRAGHI F, TODESCHINI M, et al. Long-term clinical and immunological profile of kidney transplant patients given mesenchymal stromal cell immunotherapy[J]. Front Immunol, 2018, 9:1359. DOI: 10.3389/fimmu.2018.01359.
    [47] ZHANG YC, LIU W, FU BS, et al. Therapeutic potentials of umbilical cord-derived mesenchymal stromal cells for ischemic-type biliary lesions following liver transplantation[J]. Cytotherapy, 2017, 19(2):194-199. DOI: 10.1016/j.jcyt.2016.11.005.
    [48] REINDERS ME, DREYER GJ, BANK JR, et al. Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study[J]. J Transl Med, 2015, 13:344. DOI: 10.1186/s12967-015-0700-0.
  • 加载中
计量
  • 文章访问数:  138
  • HTML全文浏览量:  133
  • PDF下载量:  12
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-06-13
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2019-09-15

目录

    /

    返回文章
    返回